Evidence map›Paper›PMID 40959596›Full record

ArticleRSC medicinal chemistry2025

Development of a nitric oxide-releasing cephalexin-based hybrid compound for enhanced antimicrobial efficacy and biofilm disruption.

Sumit Kumar, Myddelton C Parker, Yi Wu, Anastasia Marx, Hitesh Handa, Elizabeth J Brisbois

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sumit KumarSchool of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia Athens GA 30602 USA ejbrisbois@uga.edu.ORCID https://orcid.org/0000-0002-4460-2682
Myddelton C ParkerSchool of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia Athens GA 30602 USA ejbrisbois@uga.edu.ORCID https://orcid.org/0009-0005-5779-2074
Yi WuSchool of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia Athens GA 30602 USA ejbrisbois@uga.edu.
Anastasia MarxSchool of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia Athens GA 30602 USA ejbrisbois@uga.edu.ORCID https://orcid.org/0009-0009-3243-9265
Hitesh HandaSchool of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia Athens GA 30602 USA ejbrisbois@uga.edu.ORCID https://orcid.org/0000-0002-9369-7374
Elizabeth J BrisboisSchool of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia Athens GA 30602 USA ejbrisbois@uga.edu.ORCID https://orcid.org/0000-0002-9283-5448

Funding

Nitric Oxide Functionalized Antibiotics to Combat Infections and Thrombosis for Extracorporeal Life SupportR01HL172496 · NHLBI · UNIVERSITY OF GEORGIA · PI Elizabeth Joy Brisbois, Hitesh Handa · 2024 to 2026
$1.5M
NHLBI NIH HHS R01 HL172496
6 · The paper itself

Abstract

Biofilm formation on medical devices and the rise of antibiotic resistance have undermined conventional antibiotics such as cephalexin (CEX), which is effective against Gram-positive infections but has limited activity against Gram-negative pathogens and biofilms. To overcome these limitations, we developed a hybrid nitric oxide (NO)-releasing conjugate (SNAP_CEX) by covalently attaching the NO donor

Identifiers

PMID40959596
PMCPMC12435586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.